title: Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke.
abstract: Osteogenic protein-1 (OP-1, BMP-7) is a member of the bone morphogenetic protein subfamily of the TGF-ss superfamily that selectively stimulates dendritic neuronal outgrowth. In previous studies, we found that the intracisternal injection of OP-1, starting at one day after stroke, enhanced sensorimotor recovery of the contralateral limbs following unilateral cerebral infarction in rats. In the current study, we further explored the time window during which intracisternal OP-1 enhances sensorimotor recovery, as assessed by limb placing tests. We found that intracisternal OP-1 (10 microg) given 1 and 3 days, or 3 and 5 days, but not 7 and 9 days after stroke, significantly enhanced recovery of forelimb and hindlimb placing. There was no difference in infarct volume between vehicle- and OP-1-treated animals. The mechanism of OP-1 action might be stimulation of new dendritic sprouting in the remaining uninjured brain.
authors.affiliation: CNS Growth Factor Research Laboratory, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
authors.forename: J
authors.initials: J
authors.lastname: Ren
authors.forename: P L
authors.initials: PL
authors.lastname: Kaplan
authors.forename: M F
authors.initials: MF
authors.lastname: Charette
authors.forename: H
authors.initials: H
authors.lastname: Speller
authors.forename: S P
authors.initials: SP
authors.lastname: Finklestein
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001835:Body Weight; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage*; D002540:Cerebral Cortex / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D003342:Corpus Striatum / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D005552:Forelimb / Q000502:physiology; D006614:Hindlimb / Q000502:physiology; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy / Q000503:physiopathology; D007276:Injections, Intraventricular; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects*; D020521:Stroke / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors; D016212:Transforming Growth Factor beta
chemical_list: C525821:Bmp7 protein, rat; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D018696:Neuroprotective Agents; D016212:Transforming Growth Factor beta